Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 2 | 9 |
| 1996 | 4 | 0 | 4 |
| 1997 | 4 | 0 | 4 |
| 1998 | 10 | 1 | 11 |
| 1999 | 4 | 0 | 4 |
| 2000 | 5 | 2 | 7 |
| 2001 | 6 | 2 | 8 |
| 2002 | 6 | 1 | 7 |
| 2003 | 17 | 1 | 18 |
| 2004 | 8 | 1 | 9 |
| 2005 | 13 | 5 | 18 |
| 2006 | 14 | 4 | 18 |
| 2007 | 19 | 2 | 21 |
| 2008 | 17 | 4 | 21 |
| 2009 | 16 | 3 | 19 |
| 2010 | 19 | 3 | 22 |
| 2011 | 37 | 4 | 41 |
| 2012 | 27 | 0 | 27 |
| 2013 | 33 | 1 | 34 |
| 2014 | 21 | 4 | 25 |
| 2015 | 44 | 2 | 46 |
| 2016 | 37 | 3 | 40 |
| 2017 | 30 | 2 | 32 |
| 2018 | 42 | 4 | 46 |
| 2019 | 43 | 3 | 46 |
| 2020 | 51 | 2 | 53 |
| 2021 | 46 | 3 | 49 |
| 2022 | 40 | 0 | 40 |
| 2023 | 43 | 0 | 43 |
| 2024 | 32 | 2 | 34 |
| 2025 | 6 | 1 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients. Cancer Discov. 2025 Apr 02; 15(4):702-716.
-
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Rep Med. 2025 Mar 18; 6(3):101983.
-
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist. 2025 Feb 06; 30(2).
-
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
-
Preoperative Chest CT Myosteatosis Indicates Worse Postoperative Survival in Stage 0-IIB Non-Small Cell Lung Cancer. Radiology. 2025 Feb; 314(2):e240282.
-
The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer. Ann Thorac Surg. 2025 Mar; 119(3):495-508.
-
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol. 2025 Jan 01; 11(1):60-69.
-
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Dec; 8:e2400373.
-
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.